
Draghi urges EU to abandon unanimity requirement
FT News Briefing
00:00
Biogen's Aduhelm Controversy and Market Reactions
This chapter examines the repercussions Biogen faces after the troubled launch of its Alzheimer's drug, Aduhelm, which has led to projected losses over a billion dollars. Additionally, it discusses the broader effects of rising interest rates on the stock market, particularly concerning tech stocks and hedge funds.
Play episode from 05:07
Transcript


